無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:前立腺癌の疫学的予測 (〜2023年)

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

発行 GlobalData 商品コード 331730
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
EpiCast Report:前立腺癌の疫学的予測 (〜2023年) EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026
出版日: 2017年11月01日 ページ情報: 英文 43 Pages
概要

世界の主要9カ国 (米国・フランス・ドイツ・イタリア・スペイン・英国・日本・ブラジル・カナダ) における前立腺癌の診断症例数は、2013年から2023年にかけて3.60%の年成長率で推移し、2013年の813,462件から2023年には1,106,349件に達すると予測されています。また、主要9ヶ国における5カ年の累積有病者数は2013年の3,381,581件から2023年までに4,618,451件へ3.66%の年成長率で拡大する見込みです。

当レポートでは、世界の主要9カ国における前立腺癌の診断症例数および死亡者数の推移について調査し、疾患の背景、リスク要因と併存症、年齢・性別・重篤度・原因病原別の診断症例数および死亡者数の予測などについてまとめています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスク要因と併存症
  • 世界の動向
    • 米国
    • EU5カ国
    • 日本・ブラジル・カナダ
  • 予測手法
    • 使用ソース
    • 未使用ソース
    • 予測の前提条件・手法
  • 前立腺癌の疫学的予測
    • 診断症例数
    • 診断症例数:年齢別
    • 標準診断事例:年齢別
    • 診断における病期
    • 5カ年の有病者数
    • 5カ年の有病者数:CRPC
    • 5カ年の有病者数:CRPC患者の骨への転移
  • 検証
    • 疫学的予測の考察
    • 分析の限界
    • 分析の強み

第4章 付録

  • 参考資料
  • 著者について
  • GlobalDataについて
  • EpiCastについて
  • 免責事項

図表

目次
Product Code: GDHCER171-17

Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.1 million men were diagnosed with prostate cancer in 2012 (IARC, 2017). In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (ACS, 2017). Approximately one in seven American men are diagnosed with prostate cancer in their lifetime. However, most are diagnosed after age 65, and patients often live long enough that they die of other causes (ACS, 2017).

In 2016, there were almost 0.5 million diagnosed incident cases of prostate cancer in the 7MM. The US had the most cases with around 150,000, or nearly 33% of cases in the 7MM, followed by Japan (about 100,000, or about 22.2% of cases). Spain had the lowest number of cases with nearly 26,000, or around 5.5% of cases in the 7MM. The number of cases in the 7MM is expected to grow to almost 550,000 by 2026, for an Annual Growth Rate (AGR) of 1.67%.

The US will still have the highest number of cases, with almost 186,000, at an AGR of over 2%, again followed by Japan (116,539 cases, AGR 1.16%). Spain will see the greatest growth (AGR around 2.5%), but will still have fewer cases than all other markets (around 32,000). Germany is expected to see the smallest increase in cases, with an AGR of nearly 1%. None of the countries are expected to see a decrease in cases.

In 2016, there were around 4.4 million prevalent cases of prostate cancer diagnosed in the previous 10 years in the 7MM. The US made up the largest share of prevalent cases with around 1.8 million or just over 42% of cases in the 7MM. Japan had the next highest number of cases with nearly 0.7 million, followed by Germany with around 540,000. Spain had the lowest number of prevalent cases, with nearly 230,000, making up only for about 5% of cases in the 7MM.

The number of 10-year prevalent cases in the 7MM is expected to increase to about 4.6 million by 2026, for an AGR of about 0.4% per year. Japan is expected to see the greatest increase in prevalent cases: our epidemiologists predict around 1 million cases in 2026, for an AGR of about 4.8%. The UK, Spain, and Italy are also expected to see an increase in the number of cases. The US will still have the greatest number of cases in 2026 (around 1.5 million), but it is expected to see the greatest decrease in cases (AGR of negative 1.47%). France and Germany are also expected to see decreases in the number of 10-year diagnosed prevalent cases.

The report "EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and global and historical trends for prostate cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. Additionally, this report forecasts 10-year prevalent cases of prostate cancer segmented by castration resistance, metastases, and HRD mutations.

Scope

  • The Prostate Cancer EpiCast Report provides an overview of the risk factors and global trends for prostate cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at 35 years), stage at diagnosis (stage I, II, III, and IV), and risk of biochemical recurrence (low, intermediate, and high) in these markets. Additionally, this report forecasts 10-year prevalent cases of prostate cancer segmented by castration resistance, metastases, and HRD mutations.
  • The Prostate Cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Prostate Cancer EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
  • Quantify patient populations in the global prostate cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
  • Understand magnitude of prostate cancer population by risk of biochemical recurrence, castration resistance, metastasis, and HRD mutations.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Prostate Cancer: Executive Summary 4

  • 2.1 Related Reports 7
  • 2.2 Upcoming Reports 7

3 Epidemiology 8

  • 3.1 Disease Background 8
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources 13
    • 3.4.2 Forecast Assumptions and Methods 18
  • 3.5 Epidemiological Forecast for Prostate Cancer (2016-2026) 25
    • 3.5.1 Diagnosed Incident Cases of Prostate Cancer 25
    • 3.5.2 Age-Specific Incident Cases of Prostate Cancer 26
    • 3.5.3 Incident Cases by Stage at Diagnosis 27
    • 3.5.4 Incident Cases by Risk of Biochemical Recurrence 27
    • 3.5.5 10-Year Diagnosed Prevalent Cases of Prostate Cancer 28
    • 3.5.6 10-Year Prevalent CRPC Cases 30
    • 3.5.7 10-Year Prevalent Metastatic Prostate Cancer Cases 30
    • 3.5.8 10-Year Prevalent mCRPC Cases with HRD Mutations 32
  • 3.6 Discussion 32
    • 3.6.1 Epidemiological Forecast Insight 32
    • 3.6.2 Limitations of Analysis 33
    • 3.6.3 Strengths of Analysis 34

4 Appendix 35

  • 4.1 Bibliography 35
  • 4.2 Primary Research - Prescriber Survey 40
  • 4.3 About the Authors 41
    • 4.3.1 Epidemiologist 41
    • 4.3.2 Reviewers 41
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology 42
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy 42
  • 4.4 About GlobalData 43
  • 4.5 Contact Us 43
  • 4.6 Disclaimer 43

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for Prostate Cancer 9
  • Table 2: AJCC Staging of Prostate Cancer 12
  • Table 3: Risk Category Definitions 18
  • Table 4: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years, Select Years, 2016-2026 25
  • Table 5: 7MM, 10-Year Diagnosed Prevalent Cases of Prostate Cancer, Men, Ages ≥35 Years, Select Years, 2016-2026 29
  • Table 6: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 40

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years, 2016 and 2026 5
  • Figure 2: 7MM, Diagnosed Prevalent Cases of Prostate Cancer, Men, Ages ≥35 Years, 2016 and 2026 6
  • Figure 3: 7MM, Age-Standardized Diagnosed Incidence of Prostate Cancer, Men, Ages ≥35 Years, 2006-2026 10
  • Figure 4: Sources Used and Not Used for Calculations of Incident Cases 13
  • Figure 5: Sources Used and Not Used for Calculations of 10-Year Diagnosed Prevalent Cases 14
  • Figure 6: Sources Used and Not Used for Calculations of Diagnosed Incident Cases by Stage at Diagnosis and Metastases 15
  • Figure 7: Sources Used and Not Used for Calculations of 10-Year Diagnosed Prevalent Cases of CRPC 16
  • Figure 8: Sources Used and Not Used for Calculations of 10-Year Diagnosed Prevalent Cases with HRD Mutations 17
  • Figure 9: 7MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years, 2016 26
  • Figure 10: 7MM, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis, Men, Ages ≥35 Years, 2016 27
  • Figure 11: 7MM, Diagnosed Incident Cases of Prostate Cancer by Risk of Biochemical Recurrence, Men, Ages ≥35 Years, 2016 28
  • Figure 12: 7MM, 10-Year Prevalent Cases of CRPC, Men, Ages ≥35 Years, 2016 30
  • Figure 13: 7MM, 10-Year Prevalent Cases of Prostate Cancer by Metastases, Men, Ages ≥35 Years, 2016 31
  • Figure 14: 7MM, 10-Year Prevalent Cases of Prostate Cancer with HRD Mutations, Men, Ages ≥35 Years, 2016 32
Back to Top